Prime Medicine vs Cradle
Side-by-side comparison of AI visibility scores, market position, and capabilities
Nasdaq-listed (PRME). $191M cash runway into 2027. IND for Wilson's Disease H1 2026. AATD IND mid-2026. $3.5B+ BMS collaboration. CGD Phase 1 showing rapid function restoration after single infusion.
About
Prime Medicine is a publicly-traded (Nasdaq: PRME) clinical-stage biotech developing Prime Editing — the most versatile and precise gene editing technology currently entering clinical trials, capable of making all 12 possible base-pair changes, small insertions, and deletions in DNA without double-strand breaks. The company has $191 million in cash runway into 2027, INDs planned for Wilson's Disease and Alpha-1 antitrypsin deficiency (AATD) in 2026, and a $55 million upfront collaboration with Bristol Myers Squibb worth up to $3.5 billion in milestones.
AI protein design platform combining language models with lab automation; active learning cycles for enzyme, antibody, and therapeutic protein engineering optimization.
About
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, activity, and manufacturability. Founded in 2021 and headquartered in Amsterdam with teams in San Francisco, Cradle raised approximately $24 million and targets biopharmaceutical, agricultural, and industrial biotechnology companies that need to engineer proteins with specific functional properties.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.